This section highlights FDA-related milestones and regulatory updates for drugs developed by Jade Biosciences (JBIO).
Over the past two years, Jade Biosciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
JADE101 and JADE201. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
JADE101 FDA Regulatory Timeline and Events
JADE101 is a drug developed by Jade Biosciences for the following indication: For the treatment of IgA nephropathy (IgAN).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- JADE101
- Announced Date:
- May 26, 2026
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc. announced that the first participant has been dosed in JUNIPER, the Company's Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN).
AI Summary
Jade Biosciences, Inc. announced that the first participant has been dosed in JUNIPER, its Phase 2 clinical trial of JADE101 for people with immunoglobulin A nephropathy (IgAN). This marks an important step forward as the company begins testing the drug in patients with this kidney disease.
IgAN is a condition that can slowly damage the kidneys, so new treatment options are needed. Jade said it expects interim Phase 2 data from the JADE101 study in 2027. The company continues to advance the program as it works to learn more about the drug’s safety and potential benefits.
Read Announcement- Drug:
- JADE101
- Announced Date:
- January 5, 2026
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc. announced its 2026 strategic priorities, including anticipated milestones ahead of the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–15, 2026, in San Francisco, California.
AI Summary
Jade Biosciences outlined its 2026 strategic priorities and expected milestones ahead of the 44th Annual J.P. Morgan Healthcare Conference (January 12–15, 2026). The company said 2026 will focus on advancing multiple clinical programs and moving lead candidate JADE101 toward later‑stage development while continuing discovery work on antibody candidates.
Key clinical near‑term milestones include biomarker‑rich interim Phase 1 data for JADE101 in healthy volunteers in the first half of 2026 to guide dose and interval selection, and initiation of a Phase 2 trial in IgA nephropathy mid‑2026 with preliminary data expected in 2027. JADE201, an extended‑half‑life anti‑BAFF‑R antibody, is planned to enter a first‑in‑human rheumatoid arthritis study in Q2 2026 with interim data in 2027. A third candidate, JADE301, is in preclinical testing and is expected to begin Phase 1 in the first half of 2027.
Jade reported about $336 million in cash and investments as of December 31, 2025, projecting runway into the first half of 2028. The company will present at the J.P. Morgan conference on January 15, 2026 at 11:15 a.m. PT, with a webcast available on its website.
Read Announcement- Drug:
- JADE101
- Announced Date:
- November 8, 2025
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc. today presented two posters for JADE101, its investigational anti-A PRoliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2025.
AI Summary
Jade Biosciences presented two posters at ASN Kidney Week 2025 on JADE101, an investigational anti-APRIL monoclonal antibody for immunoglobulin A nephropathy (IgAN). JADE101 is designed to selectively block APRIL, a driver of pathogenic IgA, and is engineered for extended half-life and patient-friendly subcutaneous dosing.
Preclinical data in non-human primates showed a favorable safety profile: JADE101 was well tolerated up to the NOAEL, had no off-target binding across >6,000 human proteins, no tissue cross-reactivity, no cytokine release, and did not broadly suppress immune cells. Treatment produced reversible reductions in immunoglobulins (IgA ~55–68%, IgM ~62–75%, IgG ~35–48%) while preserving antibody responses to a test vaccine.
Translational modeling found APRIL binding affinity predicts in vivo IgA lowering and that pharmacokinetic and biomarker responses were consistent between healthy volunteers and IgAN patients (IgA kinetics r=0.93; Gd-IgA1 vs total IgA r=0.96). Early IgA reduction correlated with later proteinuria improvement (r=0.89).
A Phase 1 single-ascending-dose trial in healthy volunteers is ongoing, with interim biomarker data expected in H1 2026 to guide dose and dosing interval for patient studies. Jade anticipates potential for infrequent subcutaneous dosing.
Read Announcement- Drug:
- JADE101
- Announced Date:
- October 19, 2025
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc. announced that it will present new preclinical safety and translational data for JADE101, its lead investigational candidate for immunoglobulin A nephropathy (IgAN), during two poster sessions at the American Society of Nephrology (ASN) Kidney Week 2025, taking place November 5–9 in Houston, Texas.
AI Summary
Jade Biosciences will present new preclinical safety and translational data for JADE101 at ASN Kidney Week 2025, November 5–9 in Houston, Texas. Two posters will share insights into the half-life-extended anti-APRIL monoclonal antibody designed to treat immunoglobulin A nephropathy (IgAN).
JADE101 selectively blocks A PRoliferation-Inducing Ligand (APRIL) to reduce abnormal IgA levels that can lead to kidney failure. Engineered for ultra-high binding affinity and extended serum half-life, JADE101 supports infrequent subcutaneous dosing. Animal studies showed potent, sustained IgA suppression and predictable pharmacokinetics without high-molecular-weight immune complexes.
The first poster, “Nonclinical Safety Profile of JADE101,” will be presented by Ashley McCord on November 8 (10:00 AM–12:00 PM CT; SA-PO0255). The second, “Translational Framework to Predict Clinical Responses to APRIL Blockade,” will be presented by Brandon Gufford (SA-PO0272). A Phase 1 healthy volunteer trial is underway, with interim data expected in the first half of 2026.
Read Announcement- Drug:
- JADE101
- Announced Date:
- September 2, 2025
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc announced that it has dosed the first cohort of participants in a Phase 1 healthy volunteer trial of JADE101.
AI Summary
Could you please provide the full text of the FDA-related news article about Jade Biosciences’ Phase 1 trial? I’ll then summarize the requested section in about 140 words with HTML paragraphs.
Read Announcement- Drug:
- JADE101
- Announced Date:
- June 9, 2025
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease.
AI Summary
Jade Biosciences, Inc. announced detailed preclinical results for its JADE101, an anti-APRIL monoclonal antibody in development for treating IgA nephropathy, a chronic autoimmune kidney disease. The study showed that JADE101 binds to APRIL with femtomolar affinity, which could allow it to completely suppress APRIL even at low drug levels. In non-human primates, a single dose resulted in a 27-day half-life and produced deep, sustained reductions in IgA for over 100 days. These findings suggest that JADE101 could support subcutaneous dosing every eight weeks or longer, making the treatment more convenient for patients. The promising preclinical profile sets the stage for a first-in-human trial scheduled for the second half of 2025, with biomarker-rich interim data expected in the first half of 2026 to help guide dose and schedule decisions.
Read Announcement- Drug:
- JADE101
- Announced Date:
- June 2, 2025
- Indication:
- For the treatment of IgA nephropathy (IgAN)
Announcement
Jade Biosciences, Inc.announced new preclinical data on JADE101, its anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy (IgAN), will be presented in an oral session during the 62nd European Renal Association (ERA) Congress, taking place in Vienna from June 4-7, 2025.
AI Summary
Jade Biosciences, Inc. has announced new preclinical data on its investigational therapy, JADE101, an anti-APRIL monoclonal antibody being developed for IgA nephropathy (IgAN). The data will be presented during an oral session at the 62nd European Renal Association (ERA) Congress in Vienna, Austria, from June 4‑7, 2025.
The session, titled “Discovery and Characterization of JADE101, an Ultra‑High Affinity, Half‑Life Extended Anti‑APRIL Monoclonal Antibody for the Treatment of IgAN,” will feature Erin Filbert, the Executive Director and Head of Research and Translational Medicine at Jade Biosciences. This presentation will focus on glomerular and tubulo‑interstitial diseases, highlighting the potential of JADE101 to reduce pathogenic IgA levels and preserve kidney function in patients suffering from IgAN.
Read Announcement
JADE201 FDA Regulatory Events
JADE201 is a drug developed by Jade Biosciences for the following indication: Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- JADE201
- Announced Date:
- May 26, 2026
- Indication:
- Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Announcement
Jade Biosciences, Inc. announced the first participant has been dosed in a first-in-human (FIH) Phase 1 clinical trial of JADE201.
AI Summary
Jade Biosciences, Inc. announced that the first participant has been dosed in its first-in-human Phase 1 clinical trial of JADE201. The study is designed to test the medicine in people for the first time and will help researchers learn more about its safety, behavior in the body, and early signs of activity.
The company said earlier preclinical work showed encouraging results, including dose-dependent BAFF-R occupancy, a longer half-life, and steady B cell depletion in non-human primates. These findings support the idea that JADE201 may work across several autoimmune diseases linked to BAFF-R biology.
Interim Phase 1 data in rheumatoid arthritis are expected in 2027 and may help the company decide which autoimmune indication to study next.
Read Announcement
Free JBIO Stock Alerts